This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
To Explore the Network Pharmacology and Molecular Docking Mechanism of Chaihu Shugan Powder with the “Same Treatment for Different Diseases” for Insomnia and Depression Based on the COVID-19 Pandemic (preprint)
researchsquare; 2022.
Preprint
in English
| PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-1332355.v2
ABSTRACT
Background:
The classic prescription Chaihu Shugan Powder (CHSGP) has been widely used in clinical Chinese medicine treatment and has clear clinical effects in the treatment of emotional diseases. Based on the increasing incidence of emotional diseases such as insomnia and depression in the population during the COVID-19 pandemic, we will explore the mechanism of CHSGP in the treatment of insomnia and depression with “Same Treatment for Different Diseases”.Methods:
Using a bioinformatics and network pharmacology platform, protein database and STRING database, we collected CHSGP chemical composition and related target data and constructed a "component-target" action network through Gene Ontology and Kyoto Encyclopedia of Genes and Genome pathway enrichment analysis. Molecular docking technology was used to verify key active ingredients and core targets.Results:
A total of 119 active compounds of CHSGP were screened, such as quercetin, kaempferol, and β-sitosterol, and 113 common related targets overlapped with insomnia and depression. GO enrichment and KEGG pathway analysis mainly involved immune, inflammation, cell proliferation, apoptosis, endocrine and other related targets and signaling pathways. Molecular docking showed that small molecular compounds (kaempferol, luteolin, quercetin, 7-methoxy-2-methyl isoflavone and beta-sitosterol) had good binding effects with five target proteins (AKT1, IL1B, IL-6, FOS, GSK3B) to play a role in regulating immunity, the inflammatory response, cell proliferation, apoptosis, and endocrine signaling.Conclusions:
Under the context of the COVID-19 pandemic, it revealed the complex mechanism of multicomponent, multitarget, and multipathway of the classic CHSGP for insomnia and depression, laying a theoretical foundation for its clinical application of its "same treatment for different diseases".
Full text:
Available
Collection:
Preprints
Database:
PREPRINT-RESEARCHSQUARE
Language:
English
Year:
2022
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS